Sanford C. Bernstein Reiterates “€115.00” Price Target for Merck KGaA (MRK)
Sanford C. Bernstein set a €115.00 ($133.72) target price on Merck KGaA (FRA:MRK) in a research report report published on Wednesday morning. The firm currently has a buy rating on the healthcare company’s stock.
Several other equities research analysts have also recently commented on the company. UBS AG set a €120.00 ($139.53) target price on Merck KGaA and gave the company a buy rating in a research note on Monday, October 23rd. equinet AG set a €112.00 ($130.23) price target on Merck KGaA and gave the stock a buy rating in a research report on Thursday, August 31st. Societe Generale set a €103.00 ($119.77) price target on Merck KGaA and gave the stock a neutral rating in a research report on Tuesday, September 5th. Goldman Sachs Group, Inc. (The) set a €105.00 ($122.09) price target on Merck KGaA and gave the stock a neutral rating in a research report on Wednesday, September 6th. Finally, Independent Research GmbH set a €105.00 ($122.09) price target on Merck KGaA and gave the stock a neutral rating in a research report on Monday, August 28th. Eleven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Merck KGaA presently has a consensus rating of Buy and an average target price of €109.00 ($126.74).
Shares of Merck KGaA (FRA:MRK) opened at €90.56 ($105.30) on Wednesday. Merck KGaA has a 12 month low of €89.21 ($103.73) and a 12 month high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Stock Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related stocks with our FREE daily email newsletter.